Surgery remains the only curative therapy for colorectal cancer (CRC); however, several studies have proved that adjuvant chemotherapy improves the curative rate. A growing body of evidence ...

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

The following is a summary of “Introducing Neoadjuvant Immunotherapy for Colorectal Cancer: Advancing the Frontier,” published in the January 2025 issue of Surgery by Orhan et al. Immunotherapy, ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...

Adjuvant Chemotherapy for Stage II Colorectal Cancer: Can Pooled Analyses Compensate? Despite an increasing number of stage II compared with stage III patients attending oncology clinics (the ...

Cancer immunotherapy drugs, which boost the immune system to fight the tumour, have revolutionised the treatment of the deficient subtype of colorectal cancer. However, these drugs only work in ...

Non-small cell lung cancer treatment (PDQ)—patient version. Food and Drug Administration. FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer. American Cancer ...

1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. 2Medical Faculty, University Duisburg-Essen, Essen, Germany. 3National Center of Tumor Diseases ...